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Expiratory positive airway pressure (EPAP) is widely applicable, either as a strategy for pulmonary 
reexpansion, elimination of pulmonary secretion or to reduce hyperinflation. However, there is no 
consensus in the literature about the real benefits of EPAP in reducing dynamic hyperinflation (DH) 
and increasing exercise tolerance in subjects with chronic obstructive pulmonary disease (COPD). To 
systematically review the effects of EPAP application during the submaximal stress test on DH and 
exercise capacity in patients with COPD. This meta‑analysis was performed from a systematic search 
in the PubMed, EMBASE, PeDRO, and Cochrane databases, as well as a manual search. Studies that 
evaluated the effect of positive expiratory pressure on DH, exercise capacity, sensation of dyspnea, 
respiratory rate, peripheral oxygen saturation, sense of effort in lower limbs, and heart rate were 
included. GRADE was used to determine the quality of evidence for each outcome. Of the 2,227 
localized studies, seven studies were included. The results show that EPAP did not change DH and 
reduced exercise tolerance in the constant load test. EPAP caused a reduction in respiratory rate 
after exercise (− 2.33 bpm; 95% CI: − 4.56 to − 0.10) (very low evidence) when using a pressure level of 
5  cmH2O. The other outcomes analyzed were not significantly altered by the use of EPAP. Our study 
demonstrates that the use of EPAP does not prevent the onset of DH and may reduce lower limb 
exercise capacity in patients with COPD. However, larger and higher‑quality studies are needed to 
clarify the potential benefit of EPAP in this population.
In patients with chronic obstructive pulmonary disease (COPD) who have emphysema, decreasing lung elas-
tic recoil pressure without changes in the elastic properties of the chest wall and increasing airway resistance 
leads to increased time for lung  emptying1. Insufficient exhalation causes increased operating lung volumes and 
progressive air trapping, resulting in  dyspnea2. Pulmonary hyperinflation that occurs at rest is known as static 
 hyperinflation3. During exercise in typical situations, to accommodate additional respiratory demands triggered 
by physical exertion, respiratory rate (RR) and tidal volume  (VT)  increase4. Patients with COPD have difficulty 
increasing  VT and increase RR because they breathe at high lung  volumes4. Increased RR reduces expiratory time 
by increasing air  trapping4. This hyperinflation that occurs during exercise is known as dynamic hyperinflation 
(DH)5. DH is defined as an increase in functional residual capacity (FRC) or end-expiratory lung volume (EELV) 
above the resting value during periods of dynamic activity such as  exercise6,7.
Several measures can be implemented to reduce DH in patients with  COPD8–10. The use of inhaled 
 bronchodilators8, as well as endurance physical  training10,11, may improve exercise-induced dyspnea and 
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hyperinflation. Ventilatory strategies, such as the pursed-lip breathing  technique9,12 and noninvasive ventilation 
(NIV), have also proved effective in reducing DH in patients with  COPD13–19. However, NIV requires the use 
of specific, expensive equipment that is not always available in healthcare facilities. Therefore, the easy-to-use, 
low-cost, expiratory positive airway pressure (EPAP) applied by a face mask aims to increase resistance in the 
expiratory phase, which would reduce physiological dead space, minute volume  (VE), and RR, with consequent 
increase of the  VT, being able to improve the length-tension relationship of the respiratory muscles, making them 
more  efficient20,21. In addition, a reduction in inspiratory overload of hyperinflated lungs in patients with COPD 
would improve neuromuscular  coupling22.
Several studies have evaluated the effects of EPAP during exercise on individuals with  COPD17,18,23–27. How-
ever, controversy persists in the literature about the effects of EPAP on  DH17,18,24,26,27 and exercise tolerance in 
individuals with  COPD17,24–27. Therefore, we conducted this systematic review and meta-analysis of available 
studies that assessed the effects of EPAP during exercise on the onset of DH, exercise tolerance, and symptom 
intensity in subjects with COPD.
Methods
Protocol and eligibility criteria. We performed this systematic review according to the Updated guid-
ance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of 
 Interventions28, which included studies with subjects with mild to very severe COPD, according to the criteria 
set by the Global Initiative for COPD (GOLD)29, with clinical stability of the disease, presenting DH (10% IC 
reduction and/or a reduction greater than 150 ml, relative to the resting value)4 after stress test and who had used 
positive expiratory pressure as a strategy to minimize the onset of DH, increase exercise capacity, and/or reduce 
dyspnea, fatigue or desaturation. Studies that used continuous positive airway pressure (CPAP) or any other 
modality of NIV were excluded. Studies were included in English and Portuguese, with any follow-up or moni-
toring time and published in full version. Studies with lack of data and/or incomplete data, gray literature and 
multiple publications in which results were repeated were excluded, and only one of these studies was included.
Search strategies. The following electronic databases were searched: MEDLINE (Access by PubMed), 
Cochrane CENTRAL, PEDro, and EMBASE (up to dezember 10, 2019). Search terms included MeSH and 
COPD-related terms, positive expiratory pressure, dynamic hyperinflation, and Exercise Tests. The terms were 
adjusted to meet the requirements of each electronic database. We selected the list of included study references 
to identify additional RCTs. A full list of terms selected for searching the electronic databases is presented as 
supplemental information (Supplementary Table S1).
Study selection and data extraction. Two reviewers separately and independently selected the study 
titles and abstracts identified in the initial research. A standard screening checklist based on eligibility criteria 
was employed for each study. Studies that did not meet the eligibility criteria according to titles or abstracts were 
excluded. The full texts of the remaining studies were retrieved for a second independent review by the two 
reviewers. For studies lacking enough information to assess eligibility criteria, we contacted the authors by email 
for additional information.
We extracted the following data from the included studies: description of study participants, intervention 
in the experimental and control groups, and description and outcome measures. Two reviewers independently 
extracted data from eligible studies. Discrepancies were resolved through discussion, and a third author was 
consulted when a consensus was not reached. We contacted the authors via email for additional information when 
studies provided incomplete descriptions. Procedures for estimating missing  data29 were performed when pos-
sible. If data were still insufficient after these processes, the results were included in the descriptive analysis only.
The primary outcome analyzed was the behavior of DH, assessed by measuring IC, with the application of 
EPAP at different pressure levels. As secondary outcomes, we assessed the impact of EPAP on exercise capacity, 
the sensation of dyspnea, respiratory rate, peripheral oxygen saturation, sense of effort in lower limbs (LL) and 
heart rate.
Assessment of bias risk. Two reviewers independently assessed the risk of bias in the included studies 
using the Cochrane Risk of Bias  Tool28. The following items were assessed for each study: selection bias (random 
sequence generation and allocation masking), performance bias (blinding of patients and investigators), detec-
tion bias (blinding of outcome assessors), attrition bias (description of losses and exclusions) and reporting bias 
(selective reporting).
Summary of evidence: GRADE‑criteria. We presented the overall assessment of the quality of evi-
dence using the GRADE approach, as recommended by the Cochrane Manual for Systematic Reviews of 
 Interventions28 (Table 3). For each specific outcome, the quality of evidence was based on five factors: (1) risk 
of bias, (2) inconsistency, (3) indirect evidence, (4) inaccuracy, and (5) other considerations (publication bias). 
Quality was reduced by one level for each of the missing factors. The GRADE approach resulted in four levels of 
evidence quality: high, moderate, low, and very low.
Data analysis. Estimates of combined effects were obtained by comparing the mean change from baseline 
to the end of the study for each group and were expressed as the weighted mean difference between groups. 
Studies in which it was not possible to calculate the standard deviation of the mean change were imputed as 
directed in the  Handbook28. Calculations were performed using a random-effects method. A p-value < 0.05 was 
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considered statistically significant. Statistical heterogeneity of treatment effects between studies was assessed 
by the Inconsistency test  I2, where values above 25% and 50% were considered indicative of moderate and high 
heterogeneity,  respectively30. All analyses were conducted using Review Manager (version 5.3). To explore het-
erogeneity between studies, we reviewed the meta-analyses by removing one article at a time to see if any indi-
vidual study explained the heterogeneity. Still, sensitivity analysis was performed taking into account the differ-
ent EPAP pressures used in the included studies (10  cmH2O and between 5 and  10cmH2O).
Results
Description of studies. The search strategy generated 2,227 records, 34 of which were considered poten-
tially relevant and were retrieved for detailed analysis. Figure 1 shows the inclusion processes. Seven studies, 
with a total of 226 patients with moderate to very severe COPD, met the eligibility criteria for the systematic 
review. Only one study was randomized and controlled, and the rest used crossover design. Table 1 summarizes 
the characteristics of these studies. Five  studies18,23,24,26,27 applied EPAP through a resistor face mask. Three stud-
ies used the 6MWT as a  protocol17,25,26 for the evaluation of the effect of EPAP, and two used CEPT in cycle 
ergometer for lower  limbs23,24. All studies used constant work rate tests, except one that used an incremental 
 test23.
Risk of bias. All studies included in the systematic review described follow-up losses and exclusions. Fifty 
percent presented adequate sequential generation, characterizing a low risk of bias for these items. In 37.5% 
of the studies, allocation confidentiality was reported, blinded outcome assessment and the intention-to-treat 
principle were used for statistical analysis, showing a moderate risk of bias. Only 25% included blinded patients 
(high risk of bias) (Table 2).
Effects of interventions. Inspiratory capacity. Five of the included studies evaluated dynamic 
 hyperinflation17,18,24,26,27. IC was compared during exercise of the lower limbs without EPAP and EPAP 10 
 cmH2O, with no significant effect on reducing the onset of DH (0.04 L; 95% CI − 0.1 to 0.2;  I2 = 0%; p = 0.70). 
This same result occurred when the pressures of 5 and 10  cmH2O were evaluated (− 0.02 L; 95% CI − 0.1 to 0.1; 
 I2 = 8%; p = 0.86) (Fig. 2), as well as in the pressure subgroup analysis presented in Table 1. Based on the GRADE 
approach, the quality of evidence for this outcome—both when considering all pressure levels and when only 10 
 cmH2O was applied—was very low (Table 4).
Exercise capacity. Two studies included the assessment of exercise capacity to the tolerable limit in an 
endurance CEPT (Tlim)24,27, and three studies used the distance covered in the  6MWT17,25,26. Tlim was com-
pared with the use of 5, 7.5, and 10  cmH2O EPAP in two studies, showing a significant reduction in exercise 
capacity when EPAP was applied at the three pressure levels used (− 214.8 seg; 95% CI − 400.2 to − 29.4;  I2 = 0%; 
p = 0.02). The same behavior was observed when the subgroups with pressures ranging from 5 to 7.5 cm  H2O 
or 7,5–10  cmH2O were analyzed (Table 3). The distance covered in the 6MWT was studied by applying the 5 
 cmH2O EPAP in one study and 10  cmH2O in the other two. No improvement in the 6MWT performance was 
observed with both pressure levels (1.7 m; 95% CI − 35.7 to 39.1;  I2 = 38%; p = 0.93) (Fig. 3). Based on the GRADE 
approach, the quality of evidence for this outcome was considered very low (Table 4).
Figure 1.  Flow diagram of the studies included. EPAP: Expiratory positive airways pressure.
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device Participants Comparator N IG/CG Age (sd) IG/CG
Gender masc. 
IG/CG Protocol Outcomes
van der Schans 
et al.23, 1994
EPAP face mask 
with unidirectional 
valve (Vital Signs, 
Totowa, USA)





8 64 (4) 8
Incremental 
CEPT in a cycle 
ergometer with an 
increment of 10 
w per minute and 
60 revolutions per 
minute in normal 
breathing and with 
5  cmH2O EPAP
CEPT with EPAP 
caused a reduction 





EPAP face mask 
with spring linear 
pressure resistor 
(Vital Signs USA) 
with unidirectional 
expiratory valve









other day and 
not randomized 
without EPAP and 
with EPAP rang-
ing from 5 to 10 
 cmH2O (average 8 
 cmH2O)
The use of EPAP 




PEP value valve 
(Respironics, USA) 
connected to a pipe 
and nozzle





50/50 71.9 (4.0)/72.1 (4.1) 26/32
6MWT in normal 
breathing and with 
5  cmH2O PEP
Increased walking 




EPAP face mask 
(Joyce, Weinmann 
Gerat für Medizin 
GmbH + Co. Ger-
many) with resistor 
(PARI PEP System 
I, Pari GmbH, 
Germany)





20 69.4 (6.4) 13
6MWT with EPAP 
ranging from 
10–20  cmH2O, 
depending on 
expiratory flow
Greater decrease in 
 SpO2 and shorter 
walking distance in 





EPAP face mask 
(Vital Signs, USA) 
and unidirectional 
inspiratory valve 
(PARI PEP System, 
Respiratory Equip-
ment, Inc., USA)





16 64.5 (7.3) 12
Constant speed 
CEPT on treadmill 
at 70–80% of 
the maximum 
speed achieved in 
incremental CEPT, 
with the use of 
approximately 7.5 
 cmH2O EPAP




face mask (PEEP 
Valve, Ambu, Den-
mark), with pre
Severe to very 
severe COPD
Control situation—
6MWT with 1 
 cmH2O EPAP
50 69.9 (7.3) 35
Application of 10 
 cmH2O EPAP dur-
ing the 6MWT
There was no 
significant change 
in the variables 










 cmH2O), with dia-
phragm (5  cmH2O) 
and EPAP-associ-
ated (10  cmH2O)





15 60.9 (12.3) 8
Constant CEPT 
in lower limb 
cycle ergom-
eter performed 
on alternate days 
and in random 
order without the 
use of EPAP, with 
5  cmH2O and 10 
 cmH2O EPAP
Reduced exercise 
capacity with 10 
 cmH2O EPAP
Table 2.  Risk of bias of included studies.
Adequate sequence 
generation Allocation concealment Blinding of patients
Blinding of outcome 
assessors




van der Schans et al.23 No No No No Yes No
Monteiro et al.18 No No No No Yes No
Nicolini et al.25 Yes Yes Yes Yes Yes No
Wibmer et al.17 Yes No No No Yes No
Goelzer et al.27 No No No No Yes No
Russo et al.26 No No No No Yes No
Gass et al.24 Yes No No No Yes No
Table 1.  Characteristics of included studies using positive expiratory pressure through a device. IG 
intervention group, CG control group, EPAP expiratory positive airway pressure, PEP positive expiratory 
pressure, CEPT cardiopulmonary exercise test, COPD chronic obstructive pulmonary disease, 6MWT 
6-min walk test, 1-RM one repetition maximum tests, f breathing frequency, IC Inspiratory capacity, SpO2 
oxyhemoglobin saturation by pulse oximetry.
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Dyspnea sensation. Five studies included in the meta-analysis evaluated the sensation of dyspnea using 
the adapted (0–10) Borg  Scale17,23–26. Two studies used only 5  cmH2O23,25, another two used 10  cmH2O17,26 and 
the last one used  both24. There was no significant reduction in the sensation of dyspnea when evaluating stud-
ies that used 5  cmH2O (− 0.2; 95% CI − 2.8 to 2.2;  I2 = 94%; p = 0.82), as well as when used only 10  cmH2O (0.4; 
95% CI − 0.4 to 1.3;  I2 = 0%; p = 0.34), or considering both pressure levels (0.04; 95% CI − 1.3 to 1.4;  I2 = 86%; 
p = 0.95) (Fig. 4). Based on the GRADE approach, the quality of evidence for this outcome was considered very 
low (Table 3).
Respiratory rate. Three studies included in the meta-analysis evaluated respiratory  rate24–26. One study 
used only a 5  cmH2O  pressure25, another used 10  cmH2O26, and the last one used  both24. 5  cmH2O EPAP caused 
a significant reduction in RR compared to controls (− 2.3 bpm; 95% CI − 4.5 to 0.1;  I2 = 0%; p = 0.04). However, 
there was no change in RR when a higher pressure level of 10  cmH2O was applied (− 0.1 bpm; 95% CI − 2.7 to 
2.4;  I2 = 0%; p = 0.90), or when the analysis was performed without stratification by EPAP pressure (− 1.4 bpm; 
95% CI − 3.0 to 0.2;  I2 = 0%; p = 0.10) (Fig. 5). Based on the GRADE approach, the quality of evidence for this 
outcome, when considering only the 5  cmH2O pressure, was low, and for 10  cmH2O, the evidence was consid-
ered very low (Table 4).
Oxyhemoglobin saturation by pulse oximetry. Five studies evaluated peripheral oxygen 
 saturation17,24–27, two used 5  cmH2O  EPAP24,25, one used 7.5  cmH2O27, and three used 10  cmH2O17,24,26. The use 
of 5  cmH2O EPAP (0.5%; 95% CI − 0.7 to 1.9;  I2 = 31%; p = 0.40), 10  cmH2O (0.7%; 95% CI − 0.9 to 2.4;  I2 = 12%; 
p = 0.39) or 5–10  cmH2O (0.5%; 95% CI − 0.4 to 1.5;  I2 = 0%; p = 0.25) did not cause significant changes in  SpO2 
during exercise (Fig. 6). The same behavior was observed when the subgroups with pressures ranging from 5 to 
7.5 cm  H2O or 7,5 to 10  cmH2O were analyzed (Table 3). Based on the GRADE approach, the quality of evidence 
for  SpO2, both when considering all pressures, and when only 5–10  cmH2O, was very low (Table 4).
Figure 2.  Comparison of inspiratory capacity without EPAP versus EPAP from 5 to 10  cmH2O. a5  cmH2O; 
b10cmH2O.
Table 3.  Analysis of pressure subgroups. Tlim total exercise time. (a) Considering the pressure level of 5 
 cmH2O; (b)Considering the pressure level of 10  cmH2O.
Outcome Subgroup analyses Result
Inspiratory capacity 5–7.5  cmH2O24(a),27 0.02 L (95% CI − 0.30 to 0.34,  I2 = 0%)
7.5–10  cmH2O17,18,24(b),26,27  − 0.05 L (95% CI − 0.24 to 0.15,  I2 = 14%)
Exercise capacity (Tlim) 5–7.5  cmH2O24(a),27  − 224.8 s (95% CI − 417.6 to − 32.0,  I2 = 0%)
7.5–10  cmH2O24(b),27  − 230.65 s (95% CI − 423.6 to − 37.6,  I2 = 0%)
Peripheral oxygen saturation 5–7.5  cmH2O24(a),25,27 0.57% (95% CI − 0.44 to 1.59,  I2 = 16%)
7.5–10  cmH2O17,24(b),26,27 0.58% (95% CI − 0.93 to 2.09,  I2 = 3%)
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Leg discomfort. Two studies evaluated lower limb discomfort with 10  cmH2O EPAP by the adapted Borg 
 Scale24,26. The use of EPAP did not modify lower limb discomfort during exercise (0.1; 95% CI − 0.3 to 0.7; 
 I2 = 0%; p = 0.53) (Fig. 7). Based on the GRADE approach, the quality of evidence for this outcome was consid-
ered very low (Table 3).
Table 4.  Quality of evidence using The GRADE approach. N (trials) number of articles with outcome 
assessment, IC Inspiratory capacity, Tlim total exercise time, 6MWT six-minute-walk-test, f breathing 
frequency, SpO2 oxyhemoglobin saturation by pulse oximetry. a Some studies do not report whether there 
was allocation concealment, whether there was blinding of patients and outcome assessors and whether the 
analysis was performed by intention to treat; bHigh heterogeneity (over 50%); cLarge confidence interval (CI).
Certainty assessment N Absolute Certainty
N (trials) Risk of Bias Inconsistency Indirectness Imprecision Intervention Comparation (95% CI)
IC 5 to 10 cmH2O
5 Very  Seriousa Not Serious Not Serious Seriousc 118 118
 − 0.02 (95% 




3 Very  Seriousa Not Serious Not Serious Seriousc 85 85
0.04 (95% 




2 Very  Seriousa Not Serious Not Serious Very  Seriousc 31 31
 − 214.8 (95% 
CI − 400.2 
to − 29.4)
Very low
6MWT distance 5 and 10 cmH2O
3 Very  Seriousa Not Serious Not Serious Very  Seriousc 120 120
1.7 (95% 
CI − 35.7 to 
39.1)
Very low
6MWT distance 10 cmH2O
2 Very  Seriousa Not Serious Not Serious Very  Seriousc 70 70
 − 21.3 (95% 




2 Very  Seriousa Not Serious Not Serious Not Serious 65 65
 − 2.3 (95% 




2 Very  Seriousa Not Serious Not Serious Very  Seriousc 65 65
 − 0.1 (95% 




2 Very  Seriousa Not Serious Not Serious Very  Seriousc 65 65
0.5 (95% 




3 Very  Seriousa Not Serious Not Serious Very  Seriousc 85 85
0.7 (95% 




5 Very  Seriousa Not Serious Not Serious Very  Seriousc 166 166
0.5 (95% 




3 Very  Seriousa Not Serious Not Serious Very  Seriousc 73 73
 − 0.2 (95% 




3 Very  Seriousa Not Serious Not Serious Very  Seriousc 85 85
0.4 (95% 
CI − 0.4 to 
1.3)
Very low
Leg discomfort 10 cmH2O
2 Very  Seriousa Not Serious Not Serious Very  Seriousc 65 65
0.1 (95% 
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Discussion
This systematic review that studied the use of EPAP during LL exercises in individuals with COPD showed that 
this device did not modify DH and reduced exercise time (Tlim) in the constant load test, while the distance 
covered in the 6MWT remained unchanged. EPAP did not change symptoms and desaturation at exercise end. 
Figure 3.  Comparison between exercise capacity with EPAP application at different pressure levels. a5  cmH2O; 
b10cmH2O.
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Figure 5.  Comparison between respiratory rate with EPAP application at different pressure levels. a5  cmH2O; 
b10cmH2O.
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At the end of the exercise the RR value presented an increase of around 3.8 ± 6.9 bpm with a 5  cmH2O EPAP, 
while controls had a greater increase of nearly 6.6 ± 5.5 bpm without the use of EPAP.
The effect of EPAP on DH in COPD was studied previously by other authors. Monteiro et al.18. evaluated 
the effect of EPAP, applied through a face mask, with an approximate pressure level of 8  cmH2O, on the onset 
of DH during submaximal exercise in patients with moderate to very severe COPD. This study demonstrated 
that the application of this pressure modality was associated with exercise-induced attenuation of DH (i.e., a 
lower decrease in inspiratory capacity (IC) immediately after exercise). Similarly, Wibmer et al.17. also observed 
a reduction in DH after performing the six-minute walk test (6MWT) with 10  cmH2O nasal EPAP in patients 
with moderate to severe COPD. Another study showed that a 5  cmH2O EPAP during exercise reduced ventilation 
and physiological dead space, but the degree of baseline hyperinflation and DH were not  evaluated23.
We hypothesized that EPAP would reduced exercise-induced DH in individuals with COPD. This effect was 
not demonstrated by this meta-analysis, in which DH, measured by serial IC measurements, did not change 
significantly by applying EPAP ranging from 5 to 20  cmH2O. One of the mechanisms that could reduce DH 
would be through the reduction of RR, which was observed in the meta-analysis. Reduction of RR with 5  cmH2O 
EPAP during LL exercise may be due to less airway collapse, which may lead to prolonged expiratory  time31,32 
and thereby reduce lung  volumes23, which could theoretically decrease  DH33. However, no reduction in DH was 
observed.
Another reason to explain the ineffectiveness of EPAP in reducing DH in some studies is the use of broncho-
dilators by patients, because it is possible that offering them to all participants before exercise may have mini-
mized the effects of positive pressure on IC. In the sample included in this meta-analysis, five studies mentioned 
long-term use of bronchodilators by  patients17,18,23–25, and three of these were associated with use of short-term 
 bronchodilators24,25. Thus, findings in patients under this condition could not be generalized to those without 
recent bronchodilator use, since the use of bronchodilators immediately before an exercise test interferes with 
the degree of DH developed during the  examination24.
Regarding the pressure level used in EPAP in the articles analyzed, these ranged from 5–10  cmH2O. Thus, 
only the study conducted by Monteiro et al.18. allowed the adjusted pressure level to be the one in which the 
patient reported greater comfort, and this level was on average 8 ± 1.5  cmH2O. It is also important to mention 
that in the study conducted by Wibmer et al.17. the minimum pressure level was 10  cmH2O, however it could 
reach up to 20  cmH2O, because the device used for positive pressure generation was based on a silicone nasal 
mask with an adjustable orifice resistor, which was generally capable of a flow-dependent expiratory pressure. 
The authors pointed out that all subjects received positive pressure with the device’s expiratory resistance set to 
the largest available opening (5.0 mm). Thus, pressure generation would be close to 10  cmH2O, but as pressure 
level generation was flow-dependent, this value may have been exceeded. However, in our meta-analysis, when 
this study was omitted to assess possible individual study influences on the outcomes, heterogeneity and weighted 
mean difference remained unchanged.
The use of EPAP reduced exercise capacity (Tlim) measured by the constant load test. It is possible that there 
has been a significant reduction in  VO2 and systolic volume assessed through the oxygen pulse, as previously 
 shown24,34, indicating compromised hemodynamic response. This finding is related to the decrease in venous 
return caused by excessive recruitment of expiratory  muscles35, which may lead to reduced ventilation/perfusion 
ratio and cardiac  output36, where such associated factors may not have allowed that the effect of EPAP on this 
outcome was demonstrated.
Another factor that may also have influenced exercise capacity is the increase in sympathetic vasomotor 
outflow during the test, which can be observed through increased expiratory  resistance37. When added to central 
hemodynamics and ventilatory restriction, all these mechanisms may contribute to an impaired exercise capac-
ity. In addition to the physiological factors mentioned, the type of test used to assess this outcome could have 
influenced the positive or negative results regarding the application of EPAP. Thus, as performed, in relation to 
the pressure level, when a study included in the meta-analysis presented a different exercise capacity test, it was 
omitted in order to observe possible individual influences on the results regarding the heterogeneity and the 
weighted mean difference; however, results remained unchanged.
Our study has several methodological strengths. These are comprehensive and systematic bibliographic 
research, the collaboration of a multidisciplinary team of health researchers, and methodologies that used explicit 
and reproducible eligibility criteria. In addition, we performed a meta-analysis to quantitatively express the results 
obtained and assess the quality of evidence for each outcome analyzed.
We found that many of the studies were methodologically limited by a high risk of bias. Only one study 
clearly presented blinding (patients and evaluators), and allocation concealment  confidentiality25. However, all 
Figure 7.  Comparison of leg discomfort assessed using the Borg scale, with 10  cmH2O EPAP. b10cmH2O.
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 studies17,18,23–27 described the losses and exclusions that occurred during the follow-up period. Thus, sensitivity 
analyzes were partially impaired by the methodological quality presented by the included studies and the small 
number of studies and participants. Moreover, the included studies do not have enough statistical power, because 
even performing the meta-analysis, the 95% confidence intervals remained quite wide. Moreover, according to 
the GRADE approach, most results presented very low quality of evidence. This indicates that any effect estimate 
is very inaccurate, and it is very likely that further research will have a more important impact on our confidence 
to estimate the effect, suggesting that further studies with a larger number of subjects and stricter methodological 
criteria should be performed.
Due to the statistical heterogeneity found in the meta-analysis, we performed a detailed exploration of sources 
of heterogeneity between studies, including a detailed description of sensitivity analysis and subgroup analysis. 
The steps used to analyze the moderate and high heterogeneities of the studies were (1) perform the meta-analysis 
removing one article at a time to check if any individual study explained the heterogeneity, and (2) perform the 
sensitivity analyses based on the pressure level used and the type of exercise test which the patients underwent. 
Despite this, in some results, both the pressure level and the type of exercise test used do not seem to influence 
the meta-analysis results.
Although the main results found in our study, some limitations need to be considered. Since five from the 
seven included studies were randomized crossover  trials17,18,23,24,26,27, the first intervention may have generated 
an impact in the following in case the washout period was insufficient. From the six studies selected, two did 
not mentioned the washout  period23,27, two reported a 48 h period and its patients underwent the  CPET18,24, 
another study reported a washout period of 2–24  h17 and the last one reported only 1 h 26, being that in the last 
two studies the patients underwent the 6MWT. Another significant limitation is the sample selection, since five 
from the seven selected studies included individuals with severe to moderate  COPD17,18,23–25 and two recruited 
individuals with severe to highly severe  COPD26,27. This data is relevant since patients with a higher severity 
of the disease may report an increased resting hyperinflation and/or DH during exercise, therefore, could have 
a greater benefit from the EPAP application. On the other hand, if the level of EPAP provided is too high for 
a patient, it may worsen the hyperinflation, have a negative effect on pulmonary mechanics, increase work of 
breathing and reduce exercise capacity.
Our study demonstrates that EPAP at different pressure levels during LL exercise in patients with COPD did 
not change DH and the distance covered in the 6MWT, but worsened performance in constant load exercise. The 
use of EPAP during exercise did not change symptom intensity, desaturation, or heart rate. There was a significant 
reduction in respiratory rate with the use of EPAP. Due to the low methodological rigor of the included articles 
and the small sample size of the studies, further randomized clinical trials should be performed to corroborate 
these findings.
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